← Leaderboards
Kai Xu
Ohio State University
$5,314,370
Attributed
$8,417,947
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.2M · FY2023–25$10M$7.5M$5M$2.5M$0
'23
'24
'25
Funding mix
By agency
NIH$8,417,947 · 4
By mechanism
U19$4,640,497 · 1
U01$1,787,578 · 1
R01$1,566,658 · 1
UH2$423,214 · 1
Top collaborators
- Jianliang Xu3 shared
Others in their field
Other Rising Stars on “Vaccines”
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- Angee Greer · Ppd Development Lp$82,531,927
- Rhea Coler · Seattle Children'S Hospital$35,184,139
- Kevin Saunders · Duke University$18,106,404
- Daniel Hunter Reirden · Westat, Inc.$16,121,731
- Jason Dickens · Duke University$12,259,409
Research focus
VaccinesViralDesignMolecular ConformationElectron MicroscopyVirusStructureNanobodiesAntibodiesEpitopesNeutralizing AntibodyScreeningSiteMemberMouse ModelGlycoprotein GFutureGlycoproteinsAnimalsInsightRational DesignGlobal HealthAntigensMonoclonal Antibodies
Grant awards (8)
Development of Broadly Neutralizing Nanobodies for Advancing AIDS Therapy$776,329
R01 · FY2025 · AI
Structure, function, and antigenicity of emerging henipavirus surface glycoproteins$597,757
U01 · FY2025 · AI · contact PI
RP5: Nanobody therapeutics against henipaviruses, arenaviruses, and structural characterization$4,640,497
U19 · FY2024 · AI · contact PI
Development of Broadly Neutralizing Nanobodies for Advancing AIDS Therapy$790,329
R01 · FY2024 · AI
Structure, function, and antigenicity of emerging henipavirus surface glycoproteins$592,064
U01 · FY2024 · AI · contact PI
Targeting glycoprotein (G) domain-III for pan-lyssavirus nanobody therapeutics$195,000
UH2 · FY2024 · AI · contact PI
Structure, function, and antigenicity of emerging henipavirus surface glycoproteins$597,757
U01 · FY2023 · AI · contact PI
Targeting glycoprotein (G) domain-III for pan-lyssavirus nanobody therapeutics$228,214
UH2 · FY2023 · AI · contact PI